【摘要】 目的 系统评价睑板腺癌（MGC）手术切除合并睑缺损重建后的有效性及安全性。方法 系统检索PubMed、Web of Science、The Cochrane Library、中国生物医学文献数据库、中国知识基础设施工程和万方数据库，检索时限均从建库至2022年4月。2位研究员独立筛选文献、提取资料并评价纳入研究的偏倚风险。使用MedCalc软件对复发率进行定量Meta分析，描述性分析其他结局。结果 研究共纳入22项回顾性病例研究文献，包括了335名患者。使用不同的睑缺损重建方式均能改善眼睑的形态和功能，加权合并复发率为7.23%。74例患者报告睫毛缺损等轻微不良反应。结论 MGC手术切除合并睑缺损重建后复发率低，眼睑形态功能恢复较好，不良反应轻微。更多还原

【Abstract】 Objective To systematically evaluate the effectiveness and safety of eyelid defect reconstruction after meibomian gland carcinoma surgery. Methods Six databases were systematically searched, including PubMed, Web of Science, Cochrane Library, China Biology Medicine disc, China National Knowledge Infrastructure and WanFang databases, from the establishment of the databases to April 12, 2022. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Meta-analysis was performed for the recurrence rate using the MedCalc software, and descriptive analysis was used for other outcomes. Results A total of 22 retrospective studies were included, including 335 cases. Using different eyelid defect reconstruction methods could improve the shape and function of the eyelid, and the pooled recurrence rate was 7.39%. Minor adverse reactions such as eyelash defects were reported in 74 cases. Conclusion The recurrence rate after surgical resection of meibomian gland carcinoma following eyelid defect reconstruction was low, the shape and function of the eyelid recovered well and the adverse reactions mild.更多还原